- Oral presentation
- Open Access
Equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis
© Flett et al; licensee BioMed Central Ltd. 2010
Published: 21 January 2010
Diffuse myocardial fibrosis (DMF) is a final endpoint in most cardiac diseases. It is missed by the late gadolinium enhancement technique. Currently, the only method to quantify DMF is biopsy, which has risk and is prone to sampling error.
We have developed a new technique Equilibrium Contrast CMR (EQ-CMR) - the first clinically applicable, robust, noninvasive method to quantify DMF and show it to be accurate against the current gold-standard of surgical myocardial biopsy.
The three elements of EQ-CMR are: a bolus of extra-cellular Gd-DTPA contrast followed by continuous infusion to achieve equilibrium; a blood sample to measure blood volume of distribution, Vd(b) (one minus haematocrit); and CMR to measure pre and post equilibrium T1 (with heart rate correction). Vd(m) is calculated, reflecting DMF.
We have developed and validated a new technique, EQ-CMR to measure diffuse myocardial fibrosis. It is a simple, reliable and clinically.
This article is published under license to BioMed Central Ltd.